KRAS and metastatic colorectal cancer: Briefly, they demonstrated the different effects of the G12 and G13 K-Ras alleles on response to cetuximab and found a significant association between the presence of a G13D mutation and survival benefit after cetuximab treatment in metastatic colorectal cancer patients [56].